Rituximab cuts autoantibodies to insulin in study

08/18/2011 | HealthDay News

Rituximab treatment worked better than a placebo in suppressing autoantibodies to insulin in patients with new-onset type 1 diabetes, a study in Diabetes found. About 40% of rituximab-treated patients had no IAAs after a year, while no patient on the placebo had the same result, researchers said.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC